Galectin Therapeutics (GALT) Misses Q2 EPS by 4c

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Berenberg Reiterates Hold on Moncler SpA (MONC:IM) (MONRY)
• Wolfe Research Starts Liftoff Mobile (LFTO) at Peerperform
• Pattern Group Inc (PTRN) PT Raised to $27 at Goldman Sachs